RESUMO
OBJECTIVE:To observe the clinical efficacy and safety of Ligustrazine injection,α-ketoacid combined with levam-lodipine in the treatment of chronic renal failure. METHODS:92 patients with chronic renal failure were randomly divided into ob-servation group(46 cases)and control group(46 cases). All patients received electrolyte,vitamins and essential amino acid,low salt,low fat,hypoglycemic and hypolipemic,anti-infection,correcting anemia and other conventional symptomatic treatment. Based on it,control group received 8 Compound α-ketoacid tablets,3 times a day + 1 Benzenesulfonic acid levamlodipine tablet, once a day. Observation group additionally received 150 mg Ligustrazine hydrochloride injection,adding into 250 ml 5% Glucose injection,intravenous infusion,once a day. The treatment course for both groups was 3 months. Clinical efficacy,and urea nitro-gen (BUN),serum creatinine (Scr),serum cystatin (CysC),low-density lipoprotein cholesterol (LDL-C),total cholesterol (TC),triglyceride (TG) levels before and after treatment and the incidence of adverse reactions in 2 groups were observed. RE-SULTS:The total effective rate in observation group was significantly higher than control group,the difference was statistically sig-nificant(P0.05). After treatment,BUN,Scr,LDL-C,TC and TG in 2 groups were significantly lower than before,and obser-vation group was lower than control group,CysC was significantly higher than before,and observation group was higher than con-trol group,the differences were statistically significant (P0.05). CONCLUSIONS:Based on conventional treatment,Ligustrazine injection,α-ketoacid combined with le-vamlodipine show obvious efficacy in the treatment of chronic renal failure,they can improve the renal functions,with good safety.